The study included more than 400 patients with a history of mild or moderate COVID-19. 

All patients originally presented with a dysfunctional RVOT conduit or stented bioprosthetic pulmonary valve.

This trend was even seen in areas where COVID-19 rates were relatively low, researchers found.

All patients included in the analysis faced a high risk of complications, researchers noted. 

This trend, however, did not carry over to women with high HDL-C levels. 

Women who received left-sided radiation or endocrine therapy appear to be impacted the most by this trend. 

Researchers hope their work can help guide future treatments for atherosclerosis and other harmful diseases. 

The study included data from more than 165,000 patients with coronary artery disease (CAD).

Shkreli's company acquired the rights to Daraprim—a 62-year-old treatment for newborns and HIV patients—and promptly raised its price from $13.50 to $750.